Cisatracurium
As of the edition of 20 October 2026, Cisatracurium is a small molecule: marketed, first approved in 1995 (US); acts on CHRNA1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Nimbex Preservative Free
- First approved
- 15 December 1995 (US)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- ASPEN PHARMA INDÚSTRIA FARMACÊUTICA LTDA; 3 holders in all
- Registered trials
- 38, 0 stopped early
- Disease areas
- Nervous system; Lungs and airways; Mental health; Bones, joints and muscles; Heart and blood vessels; Injuries
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Cisatracurium.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA1 | Acetylcholine receptor subunit alpha | P02708 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 12 | 2 | 0 |
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 15 | 5 | 0 | 0 |
| All trials | 38 |